247 related articles for article (PubMed ID: 22740207)
1. Overexpression of βIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer.
Zheng WE; Chen H; Yuan SF; Wu LL; Zhang W; Sun HY; Chen WJ
J BUON; 2012; 17(2):284-90. PubMed ID: 22740207
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Inal A; Kaplan MA; Kucukoner M; Isikdogan A
Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
[TBL] [Abstract][Full Text] [Related]
3. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer.
Wei J; Costa C; Ding Y; Zou Z; Yu L; Sanchez JJ; Qian X; Chen H; Gimenez-Capitan A; Meng F; Moran T; Benlloch S; Taron M; Rosell R; Liu B
J Natl Cancer Inst; 2011 Oct; 103(20):1552-6. PubMed ID: 21862729
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
5. [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Dong NN; Wang MY; Zhang Q; Liu ZF
Ai Zheng; 2009 Apr; 28(4):412-5. PubMed ID: 19622303
[TBL] [Abstract][Full Text] [Related]
6. The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation.
Drebber U; Baldus SE; Nolden B; Grass G; Bollschweiler E; Dienes HP; Hölscher AH; Mönig SP
Oncol Rep; 2008 Jun; 19(6):1477-83. PubMed ID: 18497953
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of YAP1 is correlated with progression, metastasis and poor prognosis in patients with gastric carcinoma.
Hu X; Xin Y; Xiao Y; Zhao J
Pathol Oncol Res; 2014 Oct; 20(4):805-11. PubMed ID: 24643316
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression.
Dai GH; Shi Y; Chen L; Lv YL; Zhong M
Hepatogastroenterology; 2012; 59(120):2439-44. PubMed ID: 22534547
[TBL] [Abstract][Full Text] [Related]
9. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer.
Urano N; Fujiwara Y; Doki Y; Kim SJ; Miyoshi Y; Noguchi S; Miyata H; Takiguchi S; Yasuda T; Yano M; Monden M
Int J Oncol; 2006 Feb; 28(2):375-81. PubMed ID: 16391792
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
[TBL] [Abstract][Full Text] [Related]
12. KLF4 expression and apoptosis-related markers in gastric cancer.
Krstic M; Stojnev S; Jovanovic L; Marjanovic G
J BUON; 2013; 18(3):695-702. PubMed ID: 24065485
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
Kos FT; Uncu D; Ozdemir N; Budakoglu B; Odabaş H; Abali H; Oksuzoglu B; Aksoy S; Zengin N
Chemotherapy; 2011; 57(3):230-5. PubMed ID: 21597287
[TBL] [Abstract][Full Text] [Related]
14. Expression of β-tubulin III and survivin in advance stage breast cancer correlates with chemotherapeutic effects of docetaxel.
Yuan SF; Zhu LJ; Zheng WE; Chen H; Wu LL; Zhang W; Sun HY; Chen WJ
Asian Pac J Cancer Prev; 2012; 13(1):361-5. PubMed ID: 22502701
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of adjuvant intraperitoneal chemotherapy effect prognosis of resectable gastric cancer.
Shi C; Yang B; Chen Q; Yang J; Fan N
Oncology; 2011; 80(5-6):289-95. PubMed ID: 21778768
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer.
Bilici A; Ustaalioglu BB; Ercan S; Seker M; Yilmaz BE; Orcun A; Gumus M
Tumour Biol; 2012 Dec; 33(6):2201-8. PubMed ID: 22890829
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes.
Miyazaki J; Hokari R; Kato S; Tsuzuki Y; Kawaguchi A; Nagao S; Itoh K; Miura S
Oncol Rep; 2002; 9(6):1307-12. PubMed ID: 12375039
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
[TBL] [Abstract][Full Text] [Related]
19. [HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis].
Wang Y; Xu JM; Liu JZ; Lin L; Ge FJ; Li SS; Liu LJ; Zhao CH
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):671-5. PubMed ID: 22340047
[TBL] [Abstract][Full Text] [Related]
20. Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer.
Li P; Qian J; Yu G; Chen Y; Liu K; Li J; Wang J
J Surg Oncol; 2012 Jan; 105(1):31-7. PubMed ID: 22161898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
